A. Walter-petrich

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

P. Cony-Makhoul, V. Ugo, E. Lippert, 2021, Blood advances.

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

A. Stamatoullas, S. Chevret, B. Quesnel, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

E. Vicaut, M. Dougados, M. Humbert, 2021, The Lancet Respiratory Medicine.

Prognosis of lymphoma in patients with known Inflammatory Bowel Disease: a French multicentre cohort study.

A. Amiot, L. Galicier, L. Beaugerie, 2020, Journal of Crohn's & colitis.

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

A. Stamatoullas, S. Chevret, B. Quesnel, 2019, Blood.

Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort

S. Chevret, V. Meignin, C. de Margerie-Mellon, 2021, European Respiratory Journal.

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

E. Vicaut, M. Dougados, M. Humbert, 2021, The Lancet Rheumatology.

Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study

E. Solary, P. Fenaux, S. Thépot, 2020, Blood.